Cambridge Healthtech Institute’s Insight Pharma group has published “Next-Generation Sequencing: Scientific and Commercial Implications of the $1,000 Genome,” a market research report on next-generation sequencing technologies and their applications. The report covers technologies on the market or under development by Applied Biosystems, GE Healthcare, Helicos BioSciences, Illumina, Reveo, Roche/454 Life Sciences, VisiGen Biotechnologies, and others. It also includes the results of a survey of researchers at life science organizations involved with gene sequencing.
The Wellcome Trust Sanger Institute’s Cancer Genome Project has released version 32 of the COSMIC (Catalog of Somatic Mutations in Cancer) database. COSMIC release 32 includes four new tumor suppressor genes and improved integration with the Ensembl genome browser. It includes information from 521,624 experiments, 235,207 tumors, 3,304 genes, and 445 fusions.